Anti-lipopolysaccharide antibodies in gram-negative bacteremia

Détails

ID Serval
serval:BIB_3B5ABB9279CC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Anti-lipopolysaccharide antibodies in gram-negative bacteremia
Périodique
Behring Institute Mitteilungen
Auteur(s)
Baumgartner  J. D.
ISSN
0301-0457
Statut éditorial
Publié
Date de publication
02/1991
Numéro
88
Pages
216-21
Notes
Journal Article
Review --- Old month value: Feb
Résumé
The experimental and clinical studies underlying the concept of cross-protection afforded by core lipopolysaccharides (LPS) antibodies are reviewed. These studies did not allow to clarify the epitope(s) and the effector mechanism(s) involved in the protection. Recently, two antilipid A IgM monoclonal antibodies, called E5 and HA-1A, have been investigated in patients with Gram-negative infections and a clinical picture of septicemia. E5 reduced the mortality of patients, bacteremic or not, but only as long as they were not in shock. A confirmatory study has been initiated. In contrast to E5, HA-1A protected patients in shock, but only when they were bacteremic at randomization. However, experimental studies have yielded contradictory results concerning the protective power of this antibody. Although the clinical studies suggest a beneficial effect of both antibodies in some patients, no definitive conclusions can be drawn until the extensive data will be published, and until further experimental investigations will have clarified the protective power of these antibodies.
Mots-clé
Antibodies, Bacterial/*therapeutic use Escherichia coli/immunology Gram-Negative Bacteria/*immunology Humans Lipopolysaccharides/*immunology Sepsis/*immunology/therapy
Pubmed
Web of science
Création de la notice
19/01/2008 19:12
Dernière modification de la notice
20/08/2019 14:31
Données d'usage